Loading...
ADAP.Y logo

Adaptimmune Therapeutics plcOTCPK:ADAP.Y Voorraadrapport

Marktkapitalisatie US$2.7m
Prijs aandeel
US$0.0036
US$1.5
99.8% ondergewaardeerd intrinsieke korting
1Y-98.7%
7D-64.0%
Portefeuillewaarde
​
Bekijk

Adaptimmune Therapeutics plc

OTCPK:ADAP.Y Voorraadrapport

Marktkapitalisatie: US$2.7m

Adaptimmune Therapeutics (ADAP.Y) Aandelenoverzicht

Adaptimmune Therapeutics plc, een biofarmaceutisch bedrijf in een commerciële fase, levert nieuwe celtherapieën voornamelijk aan kankerpatiënten in de Verenigde Staten en het Verenigd Koninkrijk. Meer informatie

ADAP.Y fundamentele analyse
Sneeuwvlok Score
Waardering2/6
Toekomstige groei0/6
Prestaties in het verleden0/6
Financiële gezondheid0/6
Dividenden0/6

Risicoanalyse

Negatief eigen vermogen

Zeer volatiele aandelenkoers in de afgelopen 3 maanden vergeleken met de US markt

Heeft geen betekenisvolle marktkapitalisatie ( $3M )

De laatste financiële rapporten zijn ouder dan 6 maanden


ADAP.Y Community Fair Values

Create Narrative

See what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 75.3% ondergewaardeerd intrinsieke korting
5022.2%Revenue growth p.a.
3.7k
23
2
55
29d ago

Adaptimmune Therapeutics plc Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Adaptimmune Therapeutics
Historische aandelenkoersen
Huidige aandelenkoersUS$0.0036
52 Week HoogtepuntUS$0.36
52 Week LaagUS$0.0001
Bèta2.42
1 maand verandering-82.00%
3 maanden verandering-87.14%
1 Jaar Verandering-98.74%
3 jaar verandering-99.74%
5 jaar verandering-99.90%
Verandering sinds IPO-99.90%

Recent nieuws en updates

ADAP.Y: Executive Transition And Deregistration Will Support Future Upside Potential

Analysts have adjusted their price target on Adaptimmune Therapeutics to $1.50, keeping it aligned with their fair value estimate as they factor in an updated discount rate of 13.43%, steady high revenue growth assumptions near 46.25%, a slightly lower projected profit margin close to 16.05%, and a marginally higher future P/E expectation near 19.36. What's in the News Adaptimmune Therapeutics plans executive changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of Adrian Rawcliffe in connection with a company restructuring (Key Developments).

ADAP.Y: Leadership Restructuring And Deregistration Will Set Up Future Upside Potential

Analysts have trimmed their price target on Adaptimmune Therapeutics to US$1.50 from US$1.50, reflecting updated assumptions around profit margin and future P/E, while keeping their fair value view unchanged. What's in the News Adaptimmune Therapeutics plans leadership changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of former CEO Adrian Rawcliffe in connection with a company restructuring (Key Developments).

ADAP.Y: Leadership Transition And Deregistration Will Shape Future Upside Potential

Narrative Update on Adaptimmune Therapeutics Analysts have kept their price target for Adaptimmune Therapeutics broadly steady at around $1.50 per share. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E that remain closely aligned with prior estimates.

ADAP.Y: Leadership And Listing Changes Will Drive Future Upside Potential

Narrative Update on Adaptimmune Therapeutics Analysts have modestly increased their price target on Adaptimmune Therapeutics by approximately 3 percent to about 1.50 dollars per share, citing slightly stronger expected revenue growth and a marginally lower future price to earnings multiple in their updated models. What's in the News Chief Financial Officer Chris Hill has been appointed Chief Executive Officer and Director, succeeding long serving executive Adrian Rawcliffe as part of a broader company restructuring, while temporarily retaining his CFO role (company announcement).

ADAP.Y: Leadership Transition And Deregistration Will Drive Further Upside Potential

Analysts have maintained their price target for Adaptimmune Therapeutics at $1.50. Modest improvements in profitability and valuation ratios are balanced by steady expectations for growth and risk.

Recent updates

ADAP.Y: Executive Transition And Deregistration Will Support Future Upside Potential

Analysts have adjusted their price target on Adaptimmune Therapeutics to $1.50, keeping it aligned with their fair value estimate as they factor in an updated discount rate of 13.43%, steady high revenue growth assumptions near 46.25%, a slightly lower projected profit margin close to 16.05%, and a marginally higher future P/E expectation near 19.36. What's in the News Adaptimmune Therapeutics plans executive changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of Adrian Rawcliffe in connection with a company restructuring (Key Developments).

ADAP.Y: Leadership Restructuring And Deregistration Will Set Up Future Upside Potential

Analysts have trimmed their price target on Adaptimmune Therapeutics to US$1.50 from US$1.50, reflecting updated assumptions around profit margin and future P/E, while keeping their fair value view unchanged. What's in the News Adaptimmune Therapeutics plans leadership changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of former CEO Adrian Rawcliffe in connection with a company restructuring (Key Developments).

ADAP.Y: Leadership Transition And Deregistration Will Shape Future Upside Potential

Narrative Update on Adaptimmune Therapeutics Analysts have kept their price target for Adaptimmune Therapeutics broadly steady at around $1.50 per share. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E that remain closely aligned with prior estimates.

ADAP.Y: Leadership And Listing Changes Will Drive Future Upside Potential

Narrative Update on Adaptimmune Therapeutics Analysts have modestly increased their price target on Adaptimmune Therapeutics by approximately 3 percent to about 1.50 dollars per share, citing slightly stronger expected revenue growth and a marginally lower future price to earnings multiple in their updated models. What's in the News Chief Financial Officer Chris Hill has been appointed Chief Executive Officer and Director, succeeding long serving executive Adrian Rawcliffe as part of a broader company restructuring, while temporarily retaining his CFO role (company announcement).

ADAP.Y: Leadership Transition And Deregistration Will Drive Further Upside Potential

Analysts have maintained their price target for Adaptimmune Therapeutics at $1.50. Modest improvements in profitability and valuation ratios are balanced by steady expectations for growth and risk.

ADAP.Y: Voluntary SEC Deregistration and Index Removals Will Unlock Future Value

Analysts have raised their price target for Adaptimmune Therapeutics from $0.98 to $1.50. This change reflects updated expectations for valuation and revised future earnings metrics.

ADAP.Y: Compliance Efforts Will Overcome Index Removal To Drive Recovery

Analysts have raised the price target for Adaptimmune Therapeutics from $0.64 to $0.98 per share. This change reflects increased optimism on future revenue growth and profit margins, despite a slightly higher discount rate.

TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies

Analysts have lowered their price target for Adaptimmune Therapeutics, citing solvency concerns, ongoing strategic uncertainty, and a lack of near-term catalysts, resulting in a revised fair value from $0.714 to $0.638. Analyst Commentary Bearish analysts cite significant solvency and sustainability concerns, questioning whether the company has sufficient financial resources to navigate near-term challenges.

TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies

Despite a modestly improved revenue growth outlook and a significantly lower forward P/E, consensus analyst sentiment has worsened, leading to a marked price target reduction from $0.96 to $0.714. What's in the News Adaptimmune Therapeutics reached a settlement with MD Anderson Cancer Center to resolve litigation related to a previous strategic alliance, with all claims to be dismissed upon payment.
User avatar

TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies

Rapid treatment network expansion and successful TECELRA launch are driving significant future revenue growth and patient access.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Mar 11
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Investors Don't See Light At End Of Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Tunnel And Push Stock Down 26%

Jan 01
Investors Don't See Light At End Of Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Tunnel And Push Stock Down 26%

Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?

Dec 15
Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?

Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

Nov 15
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Sep 12

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 03

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Adaptimmune: Drug Approval Now Imminent?

Feb 02

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

Sep 20

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Rendement voor aandeelhouders

ADAP.YUS BiotechsUS Markt
7D-64.0%-2.5%0.8%
1Y-98.7%26.8%27.7%

Rendement versus industrie: ADAP.Y presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 26.8 % opleverde.

Rendement versus markt: ADAP.Y presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 27.7 % opleverde.

Prijsvolatiliteit

Is ADAP.Y's price volatile compared to industry and market?
ADAP.Y volatility
ADAP.Y Average Weekly Movement2,793.0%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.3%

Stabiele aandelenkoers: De aandelenkoers van ADAP.Y is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ADAP.Y is het afgelopen jaar gestegen van 1403% naar 2793%.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2008506Chris Hillwww.adaptimmune.com

Adaptimmune Therapeutics plc, een biofarmaceutisch bedrijf in een commerciële fase, levert nieuwe celtherapieën voornamelijk aan kankerpatiënten in de Verenigde Staten en het Verenigd Koninkrijk. Het ontwikkelt TECELRA ((famitresgene autoleucel of afami-cel), een genetisch gemodificeerde autologe T-cel immuuntherapie voor de behandeling van volwassenen met niet-resectabel of metastatisch synoviaal sarcoom; Lete-cel voor de behandeling van synoviaal sarcoom en myxoid liposarcoom; en ADP-5701, dat zich in Fase 1 van het klinisch onderzoek bevindt voor de behandeling van hoofd-halskanker. Het bedrijf richt zich ook op de ontwikkeling van T-celtherapieën gericht tegen PRAME (ADP-600) en CD70 (ADP-520).

Adaptimmune Therapeutics plc Samenvatting

Hoe verhouden de winst en inkomsten van Adaptimmune Therapeutics zich tot de beurswaarde?
ADAP.Y fundamentele statistieken
MarktkapitalisatieUS$2.65m
Inkomsten(TTM)-US$169.76m
Inkomsten(TTM)US$65.09m
0.0x
P/S-verhouding
0.0x
Koers/Winstverhouding

Is ADAP.Y overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ADAP.Y resultatenrekening (TTM)
InkomstenUS$65.09m
Kosten van inkomstenUS$128.69m
Brutowinst-US$63.61m
Overige uitgavenUS$106.15m
Inkomsten-US$169.76m

Laatst gerapporteerde inkomsten

Jun 30, 2025

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-0.64
Brutomarge-97.73%
Nettowinstmarge-260.82%
Schuld/Eigen Vermogen Verhouding-36.2%

Hoe presteerde ADAP.Y op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/01 18:12
Aandelenkoers aan het einde van de dag2026/05/01 00:00
Inkomsten2025/06/30
Jaarlijkse inkomsten2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Adaptimmune Therapeutics plc wordt gevolgd door 8 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Ying HuangBofA Global Research
Mohit BansalCitigroup Inc
Reni BenjaminRaymond James & Associates